Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.
Geyer CE Jr, Untch M, Huang CS, Mano MS, Mamounas EP, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, D'Hondt V, Conlin AK, Guarneri V, Wapnir IL, Jackisch C, Arce-Salinas C, Fasching PA, DiGiovanna MP, Crown JP, Wuelfing P, Shao Z, Rota Caremoli E, Bonnefoi HR, Hennessy BT, Stamatovic L, Castro-Salguero H, Brufsky AM, Knott A, Siddiqui A, Lambertini C, Boulet T, Nyawira B, Restuccia E, Loibl S; KATHERINE Study Group. Geyer CE Jr, et al. Among authors: crown jp. N Engl J Med. 2025 Jan 16;392(3):249-257. doi: 10.1056/NEJMoa2406070. N Engl J Med. 2025. PMID: 39813643 Clinical Trial.
Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer.
Browne IM, McLaughlin RA, Weadick CS, O'Sullivan S, McSorley LM, Hadi DK, Millen SJ, Higgins MJ, Crown JP, Prichard RS, McCartan DP, Hill AD, Connolly RM, Noonan SA, O'Mahony D, Murray C, O'Hanlon-Brown C, Hennessy BT, Quinn CM, Kelly CM, O'Reilly S, Morris PG, Walshe JM. Browne IM, et al. Among authors: crown jp. Breast Cancer Res Treat. 2024 Oct 4. doi: 10.1007/s10549-024-07486-5. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39365509
Real-World Analysis of the Clinical and Economic Impact of the 21-Gene Recurrence Score (RS) in Invasive Lobular Early-Stage Breast Carcinoma in Ireland.
McSorley LM, Tharmabala M, Al Rahbi F, Keane F, Evoy D, Geraghty JG, Rothwell J, McCartan DP, Greally M, O'Connor M, O'Mahony D, Keane M, Kennedy MJ, O'Reilly S, Millen SJ, Crown JP, Kelly CM, Prichard RS, Quinn CM, Walshe JM. McSorley LM, et al. Among authors: crown jp. Curr Oncol. 2024 Mar 1;31(3):1302-1310. doi: 10.3390/curroncol31030098. Curr Oncol. 2024. PMID: 38534931 Free PMC article.
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: [email protected]; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: [email protected], et al. Lancet. 2023 Apr 15;401(10384):1277-1292. doi: 10.1016/S0140-6736(23)00285-4. Lancet. 2023. PMID: 37061269 Free PMC article.
A careful reassessment of anthracycline use in curable breast cancer.
Hurvitz SA, McAndrew NP, Bardia A, Press MF, Pegram M, Crown JP, Fasching PA, Ejlertsen B, Yang EH, Glaspy JA, Slamon DJ. Hurvitz SA, et al. Among authors: crown jp. NPJ Breast Cancer. 2021 Oct 8;7(1):134. doi: 10.1038/s41523-021-00342-5. NPJ Breast Cancer. 2021. PMID: 34625570 Free PMC article. Review.
Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland.
McSorley LM, Tharmabala M, Al Rahbi F, McSorley K, Chew S, Evoy D, Geraghty JG, Prichard RS, Rothwell J, McCartan DP, McDermott EW, Keane M, Kennedy MJ, O'Reilly S, Millen SJ, Crown JP, Smyth LM, Kelly CM, Quinn CM, Walshe JM. McSorley LM, et al. Among authors: crown jp. Breast Cancer Res Treat. 2021 Aug;188(3):789-798. doi: 10.1007/s10549-021-06211-w. Epub 2021 Apr 9. Breast Cancer Res Treat. 2021. PMID: 33835293
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.
Fehrenbacher L, Cecchini RS, Geyer CE Jr, Rastogi P, Costantino JP, Atkins JN, Crown JP, Polikoff J, Boileau JF, Provencher L, Stokoe C, Moore TD, Robidoux A, Flynn PJ, Borges VF, Albain KS, Swain SM, Paik S, Mamounas EP, Wolmark N. Fehrenbacher L, et al. Among authors: crown jp. J Clin Oncol. 2020 Feb 10;38(5):444-453. doi: 10.1200/JCO.19.01455. Epub 2019 Dec 10. J Clin Oncol. 2020. PMID: 31821109 Free PMC article. Clinical Trial.
BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer.
Walsh L, Haley KE, Moran B, Mooney B, Tarrant F, Madden SF, Di Grande A, Fan Y, Das S, Rueda OM, Dowling CM, Varešlija D, Chin SF, Linn S, Young LS, Jirström K, Crown JP, Bernards R, Caldas C, Gallagher WM, O'Connor DP, Ní Chonghaile T. Walsh L, et al. Among authors: crown jp. Clin Cancer Res. 2019 Dec 1;25(23):7139-7150. doi: 10.1158/1078-0432.CCR-19-0713. Epub 2019 Aug 13. Clin Cancer Res. 2019. PMID: 31409615
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. von Minckwitz G, et al. Among authors: crown jp. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. N Engl J Med. 2019. PMID: 30516102 Clinical Trial.
56 results